Early amniocentesis: outcome, risks, and technical problems at less than or equal to 12.8 weeks

Area of Science:

• Perinatal medicine
• Prenatal diagnostics
• Medical genetics

Background:

• First-trimester genetic amniocentesis provides crucial prenatal diagnostic information.
• Evaluating the safety and efficacy of amniocentesis performed at or before 12 weeks' gestation is important for early pregnancy management.

Purpose of the Study:

• To assess the experience and outcomes of amniocentesis performed at less than or equal to 12 weeks' gestation.
• To determine the safety and viability of early-onset genetic amniocentesis.

Main Methods:

• Retrospective review of 936 patients undergoing genetic amniocentesis between 12 and 12.8 weeks' gestation.
• Data collected included gestational age, indications for the procedure, needle insertion frequency, complications, and pregnancy outcomes.

Main Results:

• The total postprocedural loss rate was 3.4% (7 miscarriages within 2 weeks, 21 before 28 weeks, 4 stillbirths/neonatal deaths).
• 2.8% of fetuses were diagnosed with chromosomal abnormalities.
• The spontaneous abortion rate in comparable non-amniocentesis pregnancies was estimated between 2.1% and 3.2%.

Conclusions:

• Amniocentesis at 12 weeks' gestation is a feasible option for obtaining early prenatal genetic diagnostic information.
• The procedure demonstrated a comparable safety profile to established methods, supporting its use in early pregnancy.